Cargando…

Ceftazidime–Avibactam for the Treatment of Multidrug-Resistant Pathogens: A Retrospective, Single Center Study

Background: Ceftazidime/avibactam is a new cephalosporin/beta-lactamase inhibitor combination approved in 2015 by the FDA for the treatment of complicated intra-abdominal and urinary tract infection, hospital-acquired pneumoniae and Gram-negative infections with limited treatment options. Methods: I...

Descripción completa

Detalles Bibliográficos
Autores principales: Di Pietrantonio, Maria, Brescini, Lucia, Candi, Jennifer, Gianluca, Morroni, Pallotta, Francesco, Mazzanti, Sara, Mantini, Paolo, Candelaresi, Bianca, Olivieri, Silvia, Ginevri, Francesco, Cesaretti, Giulia, Castelletti, Sefora, Cocci, Emanuele, Polo, Rosaria G., Cerutti, Elisabetta, Simonetti, Oriana, Cirioni, Oscar, Tavio, Marcello, Giacometti, Andrea, Barchiesi, Francesco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8944595/
https://www.ncbi.nlm.nih.gov/pubmed/35326784
http://dx.doi.org/10.3390/antibiotics11030321
_version_ 1784673754621673472
author Di Pietrantonio, Maria
Brescini, Lucia
Candi, Jennifer
Gianluca, Morroni
Pallotta, Francesco
Mazzanti, Sara
Mantini, Paolo
Candelaresi, Bianca
Olivieri, Silvia
Ginevri, Francesco
Cesaretti, Giulia
Castelletti, Sefora
Cocci, Emanuele
Polo, Rosaria G.
Cerutti, Elisabetta
Simonetti, Oriana
Cirioni, Oscar
Tavio, Marcello
Giacometti, Andrea
Barchiesi, Francesco
author_facet Di Pietrantonio, Maria
Brescini, Lucia
Candi, Jennifer
Gianluca, Morroni
Pallotta, Francesco
Mazzanti, Sara
Mantini, Paolo
Candelaresi, Bianca
Olivieri, Silvia
Ginevri, Francesco
Cesaretti, Giulia
Castelletti, Sefora
Cocci, Emanuele
Polo, Rosaria G.
Cerutti, Elisabetta
Simonetti, Oriana
Cirioni, Oscar
Tavio, Marcello
Giacometti, Andrea
Barchiesi, Francesco
author_sort Di Pietrantonio, Maria
collection PubMed
description Background: Ceftazidime/avibactam is a new cephalosporin/beta-lactamase inhibitor combination approved in 2015 by the FDA for the treatment of complicated intra-abdominal and urinary tract infection, hospital-acquired pneumoniae and Gram-negative infections with limited treatment options. Methods: In this retrospective study, we evaluate the efficacy of ceftazidime/avibactam treatment in 81 patients with Gram-negative infection treated in our center from January 2018 to December 2019. The outcome evaluated was 30-days survival or relapse of infection after the first positive blood culture. Results: the majority of patients were 56 male (69%), with median age of 67. Charlson’s Comorbidity Index was >3 in 58 patients. In total, 46% of the patients were admitted into the medical unit, 41% in the ICU, and 14% in the surgical ward. Of the patients, 78% had nosocomial infections, and 22% had healthcare-related infections. The clinical failure rate was 35%: 13 patients died within 30 days from the onset of infection. The outcome was influenced by the clinical condition of the patients: solid organ transplantation (p = 0.003) emerged as an independent predictor of mortality; non-survival patients most frequently had pneumonia (p = 0.009) or mechanical ventilation (p = 0.049). Conclusion: Ceftazidime–avibactam showed high efficacy in infections caused by MDR Gram-negative pathogens with limited therapeutic options.
format Online
Article
Text
id pubmed-8944595
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-89445952022-03-25 Ceftazidime–Avibactam for the Treatment of Multidrug-Resistant Pathogens: A Retrospective, Single Center Study Di Pietrantonio, Maria Brescini, Lucia Candi, Jennifer Gianluca, Morroni Pallotta, Francesco Mazzanti, Sara Mantini, Paolo Candelaresi, Bianca Olivieri, Silvia Ginevri, Francesco Cesaretti, Giulia Castelletti, Sefora Cocci, Emanuele Polo, Rosaria G. Cerutti, Elisabetta Simonetti, Oriana Cirioni, Oscar Tavio, Marcello Giacometti, Andrea Barchiesi, Francesco Antibiotics (Basel) Article Background: Ceftazidime/avibactam is a new cephalosporin/beta-lactamase inhibitor combination approved in 2015 by the FDA for the treatment of complicated intra-abdominal and urinary tract infection, hospital-acquired pneumoniae and Gram-negative infections with limited treatment options. Methods: In this retrospective study, we evaluate the efficacy of ceftazidime/avibactam treatment in 81 patients with Gram-negative infection treated in our center from January 2018 to December 2019. The outcome evaluated was 30-days survival or relapse of infection after the first positive blood culture. Results: the majority of patients were 56 male (69%), with median age of 67. Charlson’s Comorbidity Index was >3 in 58 patients. In total, 46% of the patients were admitted into the medical unit, 41% in the ICU, and 14% in the surgical ward. Of the patients, 78% had nosocomial infections, and 22% had healthcare-related infections. The clinical failure rate was 35%: 13 patients died within 30 days from the onset of infection. The outcome was influenced by the clinical condition of the patients: solid organ transplantation (p = 0.003) emerged as an independent predictor of mortality; non-survival patients most frequently had pneumonia (p = 0.009) or mechanical ventilation (p = 0.049). Conclusion: Ceftazidime–avibactam showed high efficacy in infections caused by MDR Gram-negative pathogens with limited therapeutic options. MDPI 2022-02-28 /pmc/articles/PMC8944595/ /pubmed/35326784 http://dx.doi.org/10.3390/antibiotics11030321 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Di Pietrantonio, Maria
Brescini, Lucia
Candi, Jennifer
Gianluca, Morroni
Pallotta, Francesco
Mazzanti, Sara
Mantini, Paolo
Candelaresi, Bianca
Olivieri, Silvia
Ginevri, Francesco
Cesaretti, Giulia
Castelletti, Sefora
Cocci, Emanuele
Polo, Rosaria G.
Cerutti, Elisabetta
Simonetti, Oriana
Cirioni, Oscar
Tavio, Marcello
Giacometti, Andrea
Barchiesi, Francesco
Ceftazidime–Avibactam for the Treatment of Multidrug-Resistant Pathogens: A Retrospective, Single Center Study
title Ceftazidime–Avibactam for the Treatment of Multidrug-Resistant Pathogens: A Retrospective, Single Center Study
title_full Ceftazidime–Avibactam for the Treatment of Multidrug-Resistant Pathogens: A Retrospective, Single Center Study
title_fullStr Ceftazidime–Avibactam for the Treatment of Multidrug-Resistant Pathogens: A Retrospective, Single Center Study
title_full_unstemmed Ceftazidime–Avibactam for the Treatment of Multidrug-Resistant Pathogens: A Retrospective, Single Center Study
title_short Ceftazidime–Avibactam for the Treatment of Multidrug-Resistant Pathogens: A Retrospective, Single Center Study
title_sort ceftazidime–avibactam for the treatment of multidrug-resistant pathogens: a retrospective, single center study
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8944595/
https://www.ncbi.nlm.nih.gov/pubmed/35326784
http://dx.doi.org/10.3390/antibiotics11030321
work_keys_str_mv AT dipietrantoniomaria ceftazidimeavibactamforthetreatmentofmultidrugresistantpathogensaretrospectivesinglecenterstudy
AT brescinilucia ceftazidimeavibactamforthetreatmentofmultidrugresistantpathogensaretrospectivesinglecenterstudy
AT candijennifer ceftazidimeavibactamforthetreatmentofmultidrugresistantpathogensaretrospectivesinglecenterstudy
AT gianlucamorroni ceftazidimeavibactamforthetreatmentofmultidrugresistantpathogensaretrospectivesinglecenterstudy
AT pallottafrancesco ceftazidimeavibactamforthetreatmentofmultidrugresistantpathogensaretrospectivesinglecenterstudy
AT mazzantisara ceftazidimeavibactamforthetreatmentofmultidrugresistantpathogensaretrospectivesinglecenterstudy
AT mantinipaolo ceftazidimeavibactamforthetreatmentofmultidrugresistantpathogensaretrospectivesinglecenterstudy
AT candelaresibianca ceftazidimeavibactamforthetreatmentofmultidrugresistantpathogensaretrospectivesinglecenterstudy
AT olivierisilvia ceftazidimeavibactamforthetreatmentofmultidrugresistantpathogensaretrospectivesinglecenterstudy
AT ginevrifrancesco ceftazidimeavibactamforthetreatmentofmultidrugresistantpathogensaretrospectivesinglecenterstudy
AT cesarettigiulia ceftazidimeavibactamforthetreatmentofmultidrugresistantpathogensaretrospectivesinglecenterstudy
AT castellettisefora ceftazidimeavibactamforthetreatmentofmultidrugresistantpathogensaretrospectivesinglecenterstudy
AT cocciemanuele ceftazidimeavibactamforthetreatmentofmultidrugresistantpathogensaretrospectivesinglecenterstudy
AT polorosariag ceftazidimeavibactamforthetreatmentofmultidrugresistantpathogensaretrospectivesinglecenterstudy
AT ceruttielisabetta ceftazidimeavibactamforthetreatmentofmultidrugresistantpathogensaretrospectivesinglecenterstudy
AT simonettioriana ceftazidimeavibactamforthetreatmentofmultidrugresistantpathogensaretrospectivesinglecenterstudy
AT cirionioscar ceftazidimeavibactamforthetreatmentofmultidrugresistantpathogensaretrospectivesinglecenterstudy
AT taviomarcello ceftazidimeavibactamforthetreatmentofmultidrugresistantpathogensaretrospectivesinglecenterstudy
AT giacomettiandrea ceftazidimeavibactamforthetreatmentofmultidrugresistantpathogensaretrospectivesinglecenterstudy
AT barchiesifrancesco ceftazidimeavibactamforthetreatmentofmultidrugresistantpathogensaretrospectivesinglecenterstudy